ClinicalTrials.gg
CompletedNCT03419897Updated Oct 26, 2024Results posted

Study of BGB-A317 in Participants With Previously Treated Unresectable HCC

A Phase 2 interventional study of Tislelizumab in Hepatocellular Carcinoma (HCC), sponsored by BeiGene. Completed at 54 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by BeiGene · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
249
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 43 studies testing tislelizumab in Carcinoma, Hepatocellular — 23 open to participants now, 25 under way, 2 of them phase 3. tislelizumab · Carcinoma, Hepatocellular.

Enrollment
3rd of 43
249 · median 40
Started
2018
the only one that year
Phase 2
31 of 43
16 open now
Registered
2nd of 43
by date
Lead sponsor
5 of 43
BeiGene

Among the 43 studies testing tislelizumab in Carcinoma, Hepatocellular, this one is the 3rd largest by enrollment, is the only one that started in 2018, is one of 31 in phase 2, and was the 2nd registered.

Carcinoma, Hepatocellular

3,653 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,065 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

23 of the 43 studies testing tislelizumab in Carcinoma, Hepatocellular are open now, in 2 countries. Recruiting first, the newest first:

18 more — sign in →

By country, each count listing its studies:

All 23 open studies →

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 741 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 251 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tislelizumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This study investigated the efficacy, safety, and pharmacokinetics of the anti-PD-1 monoclonal antibody BGB-A317 in participants with previously treated hepatocellular unresectable carcinoma.

03

Conditions studied

  • Hepatocellular Carcinoma (HCC)

Keywords

  • Advanced liver cancer
  • RATIONALE-208
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. confirmed HCC
  2. Participants with Barcelona Clinic Liver Cancer (BCLC) Stage C, or BCLC stage B not amenable to locoregional therapy or after locoregional therapy, and not amenable to a curative treatment approach
  3. Has received at least 1 for unresectable HCC
  4. Has at least 1 as defined per v1.1
  5. score A
  6. Easter Cooperative Oncology Group () Performance Status ≤ 1
  7. Adequate organ function

Key Exclusion Criteria:

  1. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC histology
  2. Prior therapies targeting or PD-L1
  3. Has known brain or
  4. Tumor thrombus involving main trunk of portal vein or inferior vena cava
  5. Loco-regional therapy to the liver within 4 weeks before enrollment
  6. Medical history of interstitial lung disease, non-infectious pneumonitis or uncontrolled systemic diseases, including diabetes, hypertension, pulmonary fibrosis, or acute lung diseases
  7. Has received:

    1. Within 28 days or 5 half-lives (whichever is shorter) of the first study drug administration: any chemotherapy, immunotherapy (eg, interleukin, interferon, thymoxin) or any therapies
    2. Within 14 days of the first study drug administration: sorafenib, regorafenib, or any Chinese herbal medicine or Chinese patent medicines used to control cancer
  8. Active diseases or history of autoimmune diseases that may relapse
  9. Participant with any condition requiring systemic treatment with either (> 10 mg daily of prednisone or equivalent) or other medication within 14 days before study drug administration

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
249 participants (actual)

Study arms

  • Experimental
    Tislelizumab

    200 milligrams once every 3 weeks

    Drug: Tislelizumab

Interventions

  • Administered intravenously

    Also known as: BGB-A317

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Assessed by Independent Review Committee (IRC)

    ORR is defined as the percentage of participants with complete response (CR) and partial response (PR) as the best overall response, as determined by an IRC using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR is defined as disappearance of all target lesions and PR is defined as at least a 30% decrease in the sum of diameters of target lesions.

    Time frame: From date of first dose to primary analysis data cut-off date of 30-June-2021 (up to approximately 3 years and 3 months)

Secondary outcomes

  1. ORR Assessed by Investigator

    ORR is defined as the percentage of participants with CR and PR as the best overall response, as determined by investigator assessment using RECIST v1.1. CR is defined as disappearance of all target lesions and PR is defined as at least a 30% decrease in the sum of diameters of target lesions.

    Time frame: From date of first dose to end of study (up to approximately 4 years and 3 months)

  2. Duration of Response (DOR) Assessed by IRC

    DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the IRC using RECIST v1.1

    Time frame: From date of first dose to end of study (up to approximately 4 years and 3 months)

  3. DOR Event-Free Rate Assessed by IRC

    DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the IRC using RECIST v1.1. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for progression or death at 12 and 24 months with 95% confidence intervals estimated using Greenwood's formula.

    Time frame: From date of first dose to end of study (up to approximately 4 years and 3 months); Months 12 and 24 reported

  4. DOR Assessed by Investigator

    DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the investigator using RECIST v1.1

    Time frame: From date of first dose to end of study (up to approximately 4 years and 3 months)

  5. DOR Event-Free Rate Assessed by Investigator

    DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the investigator using RECIST v1.1. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for progression or death at 12 and 24 months with 95% confidence intervals estimated using Greenwood's formula.

    Time frame: From date of first dose to end of study (up to approximately 4 years and 3 months); Months 12 and 24 reported

  6. Progression-free Survival (PFS) Assessed by IRC

    PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by the IRC using RECIST v1.1

    Time frame: From date of first dose to end of study (up to approximately 4 years and 3 months)

  7. PFS Assessed by Investigator

    PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by the investigator using RECIST v1.1

    Time frame: From date of first dose to end of study (up to approximately 4 years and 3 months)

  8. Overall Survival (OS)

    OS is defined as the time from first study drug administration to the date of death due to any cause

    Time frame: From date of first dose to end of study (up to approximately 4 years and 3 months)

  9. Disease Control Rate (DCR) Assessed by IRC

    DCR is defined as the percentage of participants whose best overall response is CR, PR, or stable disease (SD) as assessed by the IRC using RECIST v1.1

    Time frame: From date of first dose to end of study (up to approximately 4 years and 3 months)

  10. DCR Assessed by Investigator

    DCR is defined as the percentage of participants whose best overall response is CR, PR, or stable disease (SD) as assessed by the investigator using RECIST v1.1

    Time frame: From date of first dose to end of study (up to approximately 4 years and 3 months)

  11. Clinical Benefit Rate (CBR) Assessed by IRC

    CBR is defined as the percentage of participants who have CR, PR, or SD of ≥ 24 weeks in duration as assessed by the IRC using RECIST v1.1

    Time frame: From date of first dose to end of study (up to approximately 4 years and 3 months)

  12. CBR Assessed by Investigator

    CBR is defined as the percentage of participants who have CR, PR, or SD of ≥ 24 weeks in duration as assessed by the investigator using RECIST v1.1

    Time frame: From date of first dose to end of study (up to approximately 4 years and 3 months)

  13. European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) Visual Analogue Score (VAS)

    Mean change from baseline in EQ-5D-5L VAS. The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.

    Time frame: Baseline to Cycle 6 Day 1 and Cycle 12 Day 1 (each cycle is 21 days)

  14. European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status

    Mean change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.

    Time frame: Baseline to Cycle 6 Day 1 and Cycle 12 Day 1 (each cycle is 21 days)

  15. EORTC QLQ - Hepatocellular Carcinoma 18 Questions (HCC18): Index Scores

    Mean change from baseline in EORTC QLQ HCC18 Index Scores. The EORTC QLQ HCC18 is a specific questionnaire module that assesses quality of life of cancer patients related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.

    Time frame: Baseline to Cycle 6 Day 1 and Cycle 12 Day 1 (each cycle is 21 days)

  16. Number of Participants With Adverse Events

    Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, physical exams, electrocardiogram results and vital signs

    Time frame: From first dose up to 30 days after the last dose of study drug; up to approximately 4 years and 3 months

07

Results

Posted Jul 27, 2023

Participant flow

This study was conducted at 73 study centers in Mainland China, Taiwan, Italy, Germany, France, Spain, Poland, and the United Kingdom.

Participant flow — Overall Study
MilestoneTislelizumab
Started249
Completed0
Not completed249
Withdrew: Death180
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject6
Withdrew: Sponsor decision61
Withdrew: Physician decision1

Outcome measures

PrimaryObjective Response Rate (ORR) Assessed by Independent Review Committee (IRC)

ORR is defined as the percentage of participants with complete response (CR) and partial response (PR) as the best overall response, as determined by an IRC using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR is defined as disappearance of all target lesions and PR is defined as at least a 30% decrease in the sum of diameters of target lesions.

Time frame:
From date of first dose to primary analysis data cut-off date of 30-June-2021 (up to approximately 3 years and 3 months)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) Assessed by Independent Review Committee (IRC)
Percentage of participantsTislelizumab
Objective Response Rate (ORR) Assessed by Independent Review Committee (IRC)12.9 (8.96 to 17.66)
Statistical analysis
  • Tislelizumab · Binomial exact test · p = 0.0001
SecondaryORR Assessed by Investigator

ORR is defined as the percentage of participants with CR and PR as the best overall response, as determined by investigator assessment using RECIST v1.1. CR is defined as disappearance of all target lesions and PR is defined as at least a 30% decrease in the sum of diameters of target lesions.

Time frame:
From date of first dose to end of study (up to approximately 4 years and 3 months)
Reported as:
Number · Percentage of participants
ORR Assessed by Investigator
Percentage of participantsTislelizumab
ORR Assessed by Investigator14.5 (10.34 to 19.45)
SecondaryDuration of Response (DOR) Assessed by IRC

DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the IRC using RECIST v1.1

Time frame:
From date of first dose to end of study (up to approximately 4 years and 3 months)
Reported as:
Median · Months
Duration of Response (DOR) Assessed by IRC
MonthsTislelizumab
Duration of Response (DOR) Assessed by IRCNA (14.6 to NA)
SecondaryDOR Event-Free Rate Assessed by IRC

DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the IRC using RECIST v1.1. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for progression or death at 12 and 24 months with 95% confidence intervals estimated using Greenwood's formula.

Time frame:
From date of first dose to end of study (up to approximately 4 years and 3 months); Months 12 and 24 reported
Reported as:
Number · Percentage of participants
DOR Event-Free Rate Assessed by IRC
Percentage of participantsTislelizumab
12 Months76.9 (57.5 to 88.3)
24 Months65.9 (45.7 to 80.1)
SecondaryDOR Assessed by Investigator

DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the investigator using RECIST v1.1

Time frame:
From date of first dose to end of study (up to approximately 4 years and 3 months)
Reported as:
Median · Months
DOR Assessed by Investigator
MonthsTislelizumab
DOR Assessed by Investigator21.4 (11.1 to NA)
SecondaryDOR Event-Free Rate Assessed by Investigator

DOR is defined as the time from the date that response criteria are first met to the date that progressive disease is objectively documented or death, whichever comes first, as assessed by the investigator using RECIST v1.1. The Kaplan-Meier method was used to estimate the percentage of participants who were event-free for progression or death at 12 and 24 months with 95% confidence intervals estimated using Greenwood's formula.

Time frame:
From date of first dose to end of study (up to approximately 4 years and 3 months); Months 12 and 24 reported
Reported as:
Number · Percentage of participants
DOR Event-Free Rate Assessed by Investigator
Percentage of participantsTislelizumab
12 Months68.1 (49.8 to 80.9)
24 Months47.4 (30.1 to 62.8)
SecondaryProgression-free Survival (PFS) Assessed by IRC

PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by the IRC using RECIST v1.1

Time frame:
From date of first dose to end of study (up to approximately 4 years and 3 months)
Reported as:
Median · Months
Progression-free Survival (PFS) Assessed by IRC
MonthsTislelizumab
Progression-free Survival (PFS) Assessed by IRC2.7 (1.4 to 2.8)
SecondaryPFS Assessed by Investigator

PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by the investigator using RECIST v1.1

Time frame:
From date of first dose to end of study (up to approximately 4 years and 3 months)
Reported as:
Median · Months
PFS Assessed by Investigator
MonthsTislelizumab
PFS Assessed by Investigator2.8 (2.6 to 4.0)
SecondaryOverall Survival (OS)

OS is defined as the time from first study drug administration to the date of death due to any cause

Time frame:
From date of first dose to end of study (up to approximately 4 years and 3 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsTislelizumab
Overall Survival (OS)13.2 (10.8 to 15.2)
SecondaryDisease Control Rate (DCR) Assessed by IRC

DCR is defined as the percentage of participants whose best overall response is CR, PR, or stable disease (SD) as assessed by the IRC using RECIST v1.1

Time frame:
From date of first dose to end of study (up to approximately 4 years and 3 months)
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR) Assessed by IRC
Percentage of participantsTislelizumab
Disease Control Rate (DCR) Assessed by IRC53.0 (46.61 to 59.34)
SecondaryDCR Assessed by Investigator

DCR is defined as the percentage of participants whose best overall response is CR, PR, or stable disease (SD) as assessed by the investigator using RECIST v1.1

Time frame:
From date of first dose to end of study (up to approximately 4 years and 3 months)
Reported as:
Number · Percentage of participants
DCR Assessed by Investigator
Percentage of participantsTislelizumab
DCR Assessed by Investigator59.0 (52.65 to 65.20)
SecondaryClinical Benefit Rate (CBR) Assessed by IRC

CBR is defined as the percentage of participants who have CR, PR, or SD of ≥ 24 weeks in duration as assessed by the IRC using RECIST v1.1

Time frame:
From date of first dose to end of study (up to approximately 4 years and 3 months)
Reported as:
Number · Percentage of participants
Clinical Benefit Rate (CBR) Assessed by IRC
Percentage of participantsTislelizumab
Clinical Benefit Rate (CBR) Assessed by IRC22.5 (17.46 to 28.19)
SecondaryCBR Assessed by Investigator

CBR is defined as the percentage of participants who have CR, PR, or SD of ≥ 24 weeks in duration as assessed by the investigator using RECIST v1.1

Time frame:
From date of first dose to end of study (up to approximately 4 years and 3 months)
Reported as:
Number · Percentage of participants
CBR Assessed by Investigator
Percentage of participantsTislelizumab
CBR Assessed by Investigator30.9 (25.24 to 37.07)
SecondaryEuropean Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) Visual Analogue Score (VAS)

Mean change from baseline in EQ-5D-5L VAS. The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.

Time frame:
Baseline to Cycle 6 Day 1 and Cycle 12 Day 1 (each cycle is 21 days)
Reported as:
Mean · Score on a scale
European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) Visual Analogue Score (VAS)
Score on a scaleTislelizumab
Baseline75.2 ± 18.36
Change at Cycle 62.4 ± 12.57
Change at Cycle 124.7 ± 13.85
SecondaryEuropean Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status

Mean change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.

Time frame:
Baseline to Cycle 6 Day 1 and Cycle 12 Day 1 (each cycle is 21 days)
Reported as:
Mean · Score on a scale
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status
Score on a scaleTislelizumab
Baseline71.8 ± 19.37
Change at Cycle 6-0.1 ± 17.50
Change at Cycle 121.1 ± 18.63
SecondaryEORTC QLQ - Hepatocellular Carcinoma 18 Questions (HCC18): Index Scores

Mean change from baseline in EORTC QLQ HCC18 Index Scores. The EORTC QLQ HCC18 is a specific questionnaire module that assesses quality of life of cancer patients related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.

Time frame:
Baseline to Cycle 6 Day 1 and Cycle 12 Day 1 (each cycle is 21 days)
Reported as:
Mean · Score on a scale
EORTC QLQ - Hepatocellular Carcinoma 18 Questions (HCC18): Index Scores
Score on a scaleTislelizumab
Baseline13.6 ± 11.33
Change at Cycle 61.4 ± 11.77
Change at Cycle 120.1 ± 8.27
SecondaryNumber of Participants With Adverse Events

Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, physical exams, electrocardiogram results and vital signs

Time frame:
From first dose up to 30 days after the last dose of study drug; up to approximately 4 years and 3 months
Reported as:
Number · Participants
Number of Participants With Adverse Events
ParticipantsTislelizumab
Participants with at least 1 TEAE236
Participants with a serious TEAE94

Adverse events

Collected over From first dose to 30 days after last dose of study drug (up to approximately 4 years and 3 months). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tislelizumab180/249 (72.3%)94/249 (37.8%)226/249 (90.8%)
Most frequent serious events
Showing 10 of 87
Most frequent serious events
EventTislelizumab
AscitesGastrointestinal disorders9/249
Hepatic failureHepatobiliary disorders7/249
PneumoniaInfections and infestations5/249
Aspartate aminotransferase increasedInvestigations5/249
Upper gastrointestinal haemorrhageGastrointestinal disorders4/249
Hepatic function abnormalHepatobiliary disorders4/249
Abdominal painGastrointestinal disorders3/249
General physical health deteriorationGeneral disorders3/249
SepsisInfections and infestations3/249
Blood bilirubin increasedInvestigations3/249
Most frequent other events
Showing 10 of 52
Most frequent other events
EventTislelizumab
Aspartate aminotransferase increasedInvestigations66/249
Alanine aminotransferase increasedInvestigations52/249
Blood bilirubin increasedInvestigations48/249
Decreased appetiteMetabolism and nutrition disorders43/249
AstheniaGeneral disorders40/249
PruritusSkin and subcutaneous tissue disorders35/249
AnaemiaBlood and lymphatic system disorders32/249
PyrexiaGeneral disorders32/249
DiarrhoeaGastrointestinal disorders30/249
CoughRespiratory, thoracic and mediastinal disorders30/249

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Tislelizumab
Mean60.3 ± 12.54
Sex: Female, Male
Sex: Female, Male(Participants)Tislelizumab
Female32
Male217
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tislelizumab
Asian123
White47
Other1
Not Reported78
Eastern Cooperative Oncology Group (ECOG) Performance Status Score
Eastern Cooperative Oncology Group (ECOG) Performance Status Score(Participants)Tislelizumab
0 = Fully Active129
1 = Restricted Activity120
08

Study locations

54 sites
  • Anhui Provincial Hospital
    Hefei, Anhui 230000, China
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui 230601, China
  • Military Hospital of China
    Beijing, Beijing 100039, China
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
  • Chinese Pla General Hospital
    Beijing, Beijing 100853, China
  • Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South)
    Guangzhou, Guangdong 510245, China
  • Nanfang Hospital of Southern Medical University
    Guangzhou, Guangdong 510515, China
  • Peking University Shenzhen Hospital
    Shenzhen, Guangdong 518036, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
  • Xuzhou Central Hospital
    Xuzhou, Jiangsu 221000, China
  • The First Affiliated Hospital of Nanchang University Branch Donghu
    Nanchang, Jiangxi 330006, China
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
  • Jilin Cancer Hospital
    Changchun, Jilin 130021, China
  • Weifang Peoples Hospital
    Weifang, Shandong 261000, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 200000, China
  • Affiliated Zhongshan Hospital of Fudan University
    Shanghai, Shanghai 200032, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin 300060, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
  • Zhejiang University College of Medicine Second Affiliated Hospital
    Hangzhou, Zhejiang 310009, China
  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310016, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
  • Hopital Beaujon
    Clichy, 92210, France
  • Hopital de La Croix Rousse
    Lyon, 69317, France
  • Chu Montpellier Hopital Saint Eloi
    Montpellier Cedex, 34295, France
  • Centre Hospitalier Universitaire Nantes Hotel Dieu
    Nantes Cedex, 44093, France
  • Hopital Larchet Chu Nice
    Nice, 6200, France
  • Groupe Hospitalier Du Haut Leveque
    Pessac Cedex, 33604, France
  • Chu de Poitiers Site de La Mileterie
    Poitiers, 86000, France
  • Centre Eugene Marquis
    Rennes, 35043, France
  • Institut Gustave Roussy
    Villejuif, 94805, France
  • Kliniken Essen Mitte Evang Huyssens Stiftung
    Essen, 45136, Germany
  • Universitatsklinikum Hamburg Eppendorf
    Hamburg, 20251, Germany
  • Klinikum Johannes Gutenberg Universitaet Mainz
    Mainz, 55131, Germany
  • Azienda Ospedaliero Universitaria Pisana
    Pisa, 56126, Italy
  • Istituto Clinico Humanitas
    Rozzano, 20089, Italy
  • Narodowy Instytut Onkologii Im Marii Skodowskiej Curie Pastwowy Instytut Badawczy
    Warszawa, 02-034, Poland
  • Hospital Universitario Vall Dhebron
    Barcelona, 08035, Spain
  • Ico Lhospitalet Hospital Duran I Reynals
    Barcelona, 08908, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Universitario Hm Madrid Sanchinarro
    Madrid, 28050, Spain
  • E Da Hospital Kaohsiung
    Kaohsiung, 82445, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
  • National Taiwan University Hospital
    Taipei, 10048, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
  • Linkou Chang Gung Memorial Hospital
    Taoyuan, 33305, Taiwan
  • Queen Elizabeth Hospital
    Birmingham, B15 2TH, United Kingdom
  • The Christie Hospital
    Greater Manchester, M20 4BX, United Kingdom
  • Royal Free Hospital London Nhs Trust
    London, NW3 2QG, United Kingdom
  • Kings College
    London, SE5 9RS, United Kingdom
  • Freeman Hospital
    NewCastle Upon Tyne, NE7 7DN, United Kingdom
09

References and documents

Publications

  • Ren Z, Ducreux M, Abou-Alfa GK, Merle P, Fang W, Edeline J, Li Z, Wu L, Assenat E, Hu S, Rimassa L, Zhang T, Blanc JF, Pan H, Ross P, Yen CJ, Tran A, Shao G, Bouattour M, Chen Y, Meyer T, Hou J, Tougeron D, Bai Y, Hou MM, Meng Z, Wu J, Li V, Chica-Duque S, Cheng AL. Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial. Liver Cancer. 2022 Oct 4;12(1):72-84. doi: 10.1159/000527175. eCollection 2023 Feb. PubMed 36872927 ↗
  • Serrano D, Podger L, Barnes G, Song J, Tang B. Psychometric validation of the EORTC QLQ-HCC18 in patients with previously treated unresectable hepatocellular carcinoma. Qual Life Res. 2022 Mar;31(3):937-950. doi: 10.1007/s11136-021-02992-1. Epub 2021 Sep 13. PubMed 34518988 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Jun 2021, 38 months.

Results were first posted in Jul 2023, 2 years after primary completion. A results delay was requested in Jun 2022.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 38 months is close to that.

Counting every sponsor, half of 430 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2018
First posted
Feb 5, 2018
StartActual
Apr 9, 2018
Primary completionActual
Jun 30, 2021
CompletionActual
Jul 6, 2022
Results delay requested
Jun 24, 2022
Results first posted
Jul 27, 2023
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03419897
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Feb 5, 2018
Start date
Apr 9, 2018
Primary completion
Jun 30, 2021
Completion
Jul 6, 2022
Results posted
Jul 27, 2023
Last update
Oct 26, 2024

Study contacts

Study Director
study director · BeiGene

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion